Koninklijke Philips N.V.

Fundamentals6.0
Price Action5.0
News Sentiment7.0
AI Rating
6.0

Key Drivers

  • High gross margins
  • Minimal free cash
  • Manageable leverage

AI
AI Summary

6.0

Philips' strategic pivot from a cost-driven turnaround to AI/cloud-enabled imaging and monitoring platforms materially reframes the investment case toward higher-margin, recurring revenue upside—however, that thesis only warrants conviction if Rembra 510(k) and FDA remediation progress on schedule and quarter‑by‑quarter free‑cash‑flow recovery is evident. Investors should therefore wait for sustained FCF improvement and demonstrable recurring revenue traction (or a confirmed Rembra approval) before increasing exposure.

PlatformPivot
RegulatoryRisk
CashFlow‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • High gross margins
  • Minimal free cash
  • Manageable leverage

PHG delivers strong operating margins and manageable leverage but near-zero free cash flow and modest ROE raise concerns about capital efficiency and earnings quality.

solidMargins
cashStrain

Price Behavior

5.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Downtrend intact
  • Below short-term mean
  • Lower highs persist

PHG is in a clear downtrend over the last month, down ~15% to $26.25 and trading ~11–12% below its $29.70 short-term average, with resistance near $32.00 and support around $26.25–$27.37.

bear
watch
Support Level: $26.25 / $26.86–$27.37
Resistance Level: $32.00

Single zero-priced entry on 2026-03-16 treated as missing data

Sentiment & News

7.0

Key News Insights:

  • AI/cloud pivot
  • High-throughput CT
  • Clinical validation push

Royal Philips accelerated a shift to AI-enabled, cloud and platform health technologies—launching the high-throughput Rembra CT, expanding cloud pathology and monitoring integrations, advancing clinical AI studies and documentation tools, and running consumer campaigns amid mixed broker praise and a small institutional stake cut.

AI

These product, platform and validation moves should boost Philips' recurring software/solution revenue potential and clinical adoption, supporting investor sentiment despite a modest institutional trim